Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Total Current Liabilities of $3.9 billion for Q1 2026, up 2.57% year-over-year from $3.8 billion in Q1 2025, and up 0.5% quarter-over-quarter from $3.9 billion in Q4 2025.
Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $3.9 billion for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 2.57% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $3.9 billion (up 2.57% YoY), while the FY2025 annual figure was $3.9 billion, up 8.32% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $3.9 billion, up from $3.9 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $4.5 billion in Q3 2025, with the low at $2.2 billion in Q1 2022.
- The 5-year median for Total Current Liabilities is $3.6 billion (2024), against an average of $3.4 billion.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 39.19% in 2022, then slipped 0.33% in 2025.
- Vertex Pharmaceuticals' Total Current Liabilities stood at $2.7 billion in 2022, then grew by 29.37% to $3.5 billion in 2023, then grew by 0.48% to $3.6 billion in 2024, then climbed by 8.32% to $3.9 billion in 2025, then gained by 0.5% to $3.9 billion in 2026.
- Business Quant data shows VRTX's Total Current Liabilities at $3.9 billion in Q1 2026, $3.9 billion in Q4 2025, and $4.5 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.94 Bn |
| Mar 31, 2026 | 3.88 Bn |
| Dec 31, 2025 | 3.86 Bn |
| Sep 30, 2025 | 4.48 Bn |
| Jun 30, 2025 | 4.14 Bn |
| Mar 31, 2025 | 3.78 Bn |
| Dec 31, 2024 | 3.56 Bn |
| Sep 30, 2024 | 3.97 Bn |
| Jun 30, 2024 | 3.55 Bn |
| Mar 31, 2024 | 3.80 Bn |
| Dec 31, 2023 | 3.55 Bn |
| Sep 30, 2023 | 3.60 Bn |
| Jun 30, 2023 | 3.35 Bn |
| Mar 31, 2023 | 3.03 Bn |
| Dec 31, 2022 | 2.74 Bn |
| Sep 30, 2022 | 2.61 Bn |
| Jun 30, 2022 | 2.56 Bn |
| Mar 31, 2022 | 2.18 Bn |
| Dec 31, 2021 | 2.14 Bn |
| Sep 30, 2021 | 1.91 Bn |